| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.BONE.2007.01.008 |
| P698 | PubMed publication ID | 17331821 |
| P2093 | author name string | Richard E Reitz | |
| Elizabeth Rosenberg | |||
| Michael P Caulfield | |||
| Erluo Chen | |||
| Risa Kagan | |||
| Anne E de Papp | |||
| Henry G Bone | |||
| Anna Buinewicz | |||
| P433 | issue | 5 | |
| P304 | page(s) | 1222-1230 | |
| P577 | publication date | 2007-01-24 | |
| P1433 | published in | Bone | Q15755003 |
| P1476 | title | A cross-sectional study of bone turnover markers in healthy premenopausal women. | |
| P478 | volume | 40 |
| Q96953531 | Are the Effects of Oral and Vaginal Contraceptives on Bone Formation in Young Women Mediated via the Growth Hormone-IGF-I Axis? |
| Q37176381 | Biomarkers for osteoporosis management: utility in diagnosis, fracture risk prediction and therapy monitoring |
| Q55002406 | Bone Turnover Status: Classification Model and Clinical Implications. |
| Q48169216 | Bone markers in polycystic ovary syndrome: A multicentre study. |
| Q50867809 | Bone remodelling is reduced by recovery from iron-deficiency anaemia in premenopausal women. |
| Q33966587 | Bone turnover is adequately suppressed in osteoporotic patients treated with bisphosphonates in daily practice. |
| Q39517981 | Bone turnover marker reference intervals in young females. |
| Q51280775 | Bone turnover markers and bone mineral density in healthy mother-daughter pairs from South India. |
| Q28074551 | Bone turnover markers: Emerging tool in the management of osteoporosis |
| Q38016073 | Bone turnover markers: use in osteoporosis |
| Q36981973 | Changes in bone resorption across the menopause transition: effects of reproductive hormones, body size, and ethnicity |
| Q34035048 | Chinese bone turnover marker study: reference ranges for C-terminal telopeptide of type I collagen and procollagen I N-terminal peptide by age and gender |
| Q53388020 | Differential effects of calcium- and vitamin D-fortified milk with FOS-inulin compared to regular milk, on bone biomarkers in Chinese pre- and postmenopausal women. |
| Q33587793 | Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate |
| Q34171858 | Establishing reference intervals for bone turnover markers in healthy postmenopausal women in a nonfasting state |
| Q36692024 | Establishing reference intervals for bone turnover markers in the healthy shanghai population and the relationship with bone mineral density in postmenopausal women |
| Q35025198 | Harmonised Australian Reference Intervals for Serum PINP and CTX in Adults |
| Q47105302 | Low bone turnover in premenopausal women with type 2 diabetes mellitus as an early process of diabetes-associated bone alterations: a cross-sectional study |
| Q37823835 | Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. |
| Q33572610 | National Bone Health Alliance Bone Turnover Marker Project: current practices and the need for US harmonization, standardization, and common reference ranges |
| Q33738711 | Parathyroid hormone-related protein for the treatment of postmenopausal osteoporosis: defining the maximal tolerable dose |
| Q33569806 | Prediction of changes in bone mineral density in postmenopausal women treated with once-weekly bisphosphonates |
| Q90450569 | Reference Intervals for Bone Turnover Markers in Korean Healthy Women |
| Q45155246 | Reference intervals of bone turnover markers determined by using their curve-fitting valley for adult females in China |
| Q38921875 | The Utility of Biomarkers in Osteoporosis Management. |
| Q35100004 | The utility of procollagen type 1 N-terminal propeptide for the bone status assessment in postmenopausal women. |
| Q28085503 | Update on primary ovarian insufficiency |
| Q39385131 | Use of CTX-I and PINP as bone turnover markers: National Bone Health Alliance recommendations to standardize sample handling and patient preparation to reduce pre-analytical variability |
| Q33572186 | Vertebral anti-fracture efficacy of strontium ranelate according to pre-treatment bone turnover |
Search more.